source
- BioNTech's mRNA cancer therapy fails to improve progression-free survival in head-neck cancer trialBioNTech reported that its experimental mRNA cancer immunotherapy, BNT 113, combined with Keytruda, did not meet the primary endpoint of progression-free survival in an interim analysis of a late-s…
- Paragon Labs hires former Apogee leadership after AbbVie acquisition and spins out hypertension unitParagon Labs announced it has brought several former Apogee Therapeutics executives onto its senior team following AbbVie's $10.9 billion purchase of Apogee. The incoming leaders include Michael H…